EP1104295A1

EP1104295A1 - Use of quaternary nitrogen compounds for prophylaxis or treatment of superinfected atopic eczema

Info

Publication number: EP1104295A1
Application number: EP99938370A
Authority: EP
Inventors: Gunhild Hamer; Bernd Traupe; Florian Wolf; Heiner Max
Original assignee: Beiersdorf AG
Current assignee: Beiersdorf AG
Priority date: 1998-08-19
Filing date: 1999-07-29
Publication date: 2001-06-06
Also published as: WO2000010556A1; DE19837549A1

Abstract

The invention relates to the use of quaternary nitrogen compounds for the prophylaxis or treatment of superinfected atopic eczema.

Description

description

Use of quaternary nitrogen compounds for the prophylaxis and treatment of superinfected atopic eczema

Healthy human skin is populated with a large number of non-pathogenic microorganisms. This so-called microflora of the skin is not only harmless, it is an important protection for the defense against opportunistic or pathogenic germs.

In the case of an existing primary infection, that is, the normal microbial colonization of the skin, new infection with high bacterial counts of one or more often physiological pathogens, for example staphylococci, but often also unphysiological pathogens, for example Candida albicans, a "superinfection" of the affected skin can occur when adverse influences come together . The normal microflora of the skin (or another body organ) is literally overgrown by the secondary pathogen.

Depending on the germ in question, such superinfections can manifest themselves in unpleasant skin symptoms (itching, unattractive external appearance) in favorable cases. In unfavorable cases, however, they can lead to extensive destruction of the skin, in the worst case even culminating in the death of the patient.

Superinfections of this kind are observed in a large number of dermatological diseases, in particular atopic eczema, including neurodermatitis. Atopic eczema generally begins with itching, reddening, scaling, oozing and crusting, whereby the areas of the skin that are affected, depending on the age of the patient, assume certain characteristic accumulations. Complications in the appearance of atopic eczema are often superinfections with various pathogens men, especially Staphylococcus aureus, which affects approximately 90% of all atopics with eczematous manifestation.

Conventional treatment methods therefore include, in addition to anti-inflammatory agents (e.g. hydrocortisone), also external substances such as various antibiotics in the narrower sense or agents with antimicrobial or antimycotic properties in the broader sense (e.g. gentian violet).

However, the conventionally used active ingredients usually have the disadvantage that they either have more or less serious side effects, resistance or intolerance, or that they have an unsanitary appearance (e.g. severe skin discoloration with gentian violet).

In individual cases, it is easily possible to fight superinfections with antibiotics, but mostly such substances have the disadvantage of unpleasant side effects. For example, patients are often allergic to penicillins, which is why appropriate treatment would be prohibited in such a case. Furthermore, topically administered antibiotics have the disadvantage that they not only free the skin flora from the secondary pathogen, but also severely impair the physiological skin flora and the natural healing process is slowed down again in this way.

The reduction of clinically pronounced atopic eczema, however, has so far always been associated with considerable inconvenience, if at all, with active substances and preparations of the prior art.

The object of the present invention was to eliminate the disadvantages of the prior art and to make available substances and preparations containing such substances, the use of which can cure superinfections, the physiological skin flora not suffering any appreciable losses.

Furthermore, it was an object of the present invention to provide substances and cosmetic or dermatological preparations containing such substances which have a prophylactic effect against superinfections. It has surprisingly been found, and this is the solution to this problem that the use of quaternary nitrogen compounds for the prophylaxis and treatment of superinfected atopic eczema remedies the disadvantages of the prior art.

In the context of the disclosure of the present invention, the term “quaternary ammonium compounds” is sometimes used synonymously for “quaternary nitrogen compounds”.

According to the invention, quaternary ammonium compounds or preparations containing quaternary ammonium compounds are extremely suitable for reducing superinfected atopic eczema or for alleviating the symptoms of superinfected eczema.

Quaternary ammonium compounds are characterized by at least one quaternary nitrogen atom and follow the basic schemes below:

(1) (2) (3)

(1) alkyl ammonium compounds

(2) Imidazolinium compounds

(3) pyridinium compounds.

Quaternary ammonium compounds with at least one long alkyl chain, such as distearyldimethylammonium chloride (DSDMA), have surface-active properties and are therefore used as cationic surfactants, e.g. B. used as wetting agents, emulsifiers, antistatic agents and as plasticizers. Predominantly short-chain quaternary ammonium compounds have microbicidal properties and are therefore used in fungicidal and bactericidal disinfectants or as algicides. The quaternary ammonium compounds used according to the invention can advantageously be selected from the group of quaternary surfactants. For example, alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous. The cationic surfactants used in the invention can be furthermore preferably selected from the group of quaternary ammonium compounds, especially benzyltrialkylammonium chlorides or bromides, such as benzyl zyldimethylstearylammoniumchlorid, further Alkyltriaikylammoniumsalze, for example cetyltrimethylammonium chloride or bromide, xyethylammoniumchloride Alkyldimethylhydro- or bromides, dialkyldimethylammonium chlorides or - bromides , Alkylamidethyltrimethylammonium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylaminoxides or alkyiaminoethyldimethylamine oxides. Cetyltrimethylammonium salts are particularly advantageous, as are polyaminoalkyl biguanides, for example polyaminopropyl biguanide.

The preparations according to the invention are particularly advantageously characterized in that the quaternary nitrogen compounds are present in concentrations of 0.001-99.00% by weight, preferably 0.01-50.00% by weight, particularly preferably 0.1-10.00% by weight .-%, each based on the total weight of the composition.

Dermatological preparations according to the invention can be in the form of aerosols, that is to say from aerosol containers, squeeze bottles or preparations sprayable by a pump device, or in the form of liquid compositions that can be applied by means of roll-on devices, but also in the form of W / O that can be applied from normal bottles and containers. or O / W emulsions, e.g. Creams or lotions. Furthermore, the preparations can advantageously be in the form of tinctures, shampoos, washing, showering or bathing preparations or powders.

In addition to water, ethanol and isopropanol, glycerol and propylene glycol, skin-caring fat or fat-like substances, such as oleic acid decyl ester, cetyl alcohol, cetylstearyl alcohol and 2-octyldodecanol, can be used as conventional cosmetic carriers for the production of the dermatological preparations according to the invention in such a way Preparations customary proportions are used as well as Schieimbiidigen substances and thickeners, such as hydroxyethyl or hydroxypropyl cellulose, polyacrylic acid, polyvinylpyrrolidone, but also in small amounts cyclic silicone oils (polydimethylsiloxanes) and liquid polymethylphenylsiloxanes of low viscosity.

The lipid phase can advantageously be selected from the following group of substances: mineral oils, mineral waxes

Oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;

Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; Alkyl benzoates;

Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiioxanes and mixed forms thereof.

The oil phase of preparations according to the invention in the form of oils, emulsions, oleogels or hydrodispersions or lipodispersions is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms. Atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms. Such ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-xyl-ethylhexyl palmitate Hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oieate, erucylerucate and synthetic, semisynthetic and natural mixtures of such esters, for example Jojoba oil.

Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms. The fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like, in particular evening primrose oil and borage oil.

Any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.

The oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C _12-1 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.

Mixtures of C ₂ -is alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C ₂ -is alkyl benzoate and isotridecyl isononanoate and mixtures of C ₁₂ i5 alkyl benzoate, _2- ethyl hexyl isostearate and isotridecyl isononanoate are particularly advantageous.

Of the hydrocarbons, paraffin oil, squaian and squaien can be used advantageously for the purposes of the present invention.

The oil phase can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.

Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention. However, other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane). Mixtures of cyclomethicone and isotridecyl isononanoate, cyclomethicone and 2-ethylhexyl isostearate are also particularly advantageous.

The aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or mono - Butyl ether, diethylene glycol monomethyl or monoethyl ether and similar products, furthermore alcohols with a low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickening agents, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, e.g. Hyaluronic acid, xanthan gum, hydroxypropyl methyl cellulose, particularly advantageously from the group of the polyacrylates, preferably a polyacrylate from the group of the so-called carbopoles, for example carbopoles of the types 980, 981, 1382, 2984, 5984, each individually or in combination.

Solid pins used in the present invention contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters.

Suitable propellants for dermatological preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.

Of course, the person skilled in the art knows that there are non-toxic propellant gases per se which would in principle be suitable for the present invention, but which should nevertheless be dispensed with, in particular chlorofluorocarbons (CFCs), because of their harmful effects on the environment or other associated circumstances.

Non-ionogenic types such as polyoxyethylene fatty alcohol ethers, for example cetylstearyl alcohol polyethylene glycol ethers with 12 or 20 attached ethylene oxide units per molecule, cetostearyl alcohol and sorbitan esters and sorbitan ester and ethylene oxide compounds (for example sorbitan ethyl monostearate and monostearate) and long-chain, high molecular weight waxy polyglycol ethers have been found to be suitable.

Cleaning agents can also be advantageous embodiments of the present invention. This is particularly advantageous since some quaternary nitrogen compounds have surfactant properties.

Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water. Due to their specific molecular structure with at least one hydrophilic and one hydrophobic part of the molecule, they ensure a reduction in the surface tension of the water, wetting of the skin, facilitating the removal and removal of dirt, easy rinsing and, if desired, foam regulation.

The hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO ^" , -OSO ₃ ^2" , -SO ₃ ^" , while the hydrophobic parts generally represent non-polar hydrocarbon residues. Surfactants are generally of type and charge of the hydrophilic part of the molecule. There are four groups:

Anionic surfactants,

Cationic surfactants,

• amphoteric surfactants and

• nonionic surfactants.

Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate: RNH ₂ ⁺ CH ₂ CH ₂ COOH X ^" (at pH = 2) X ^' = any anion, for example Cl ^"

RNH ₂ ⁺ CH ₂ CH ₂ COO ^" (at pH = 7)

RNHCH ₂ CH ₂ COO ^" B ⁺ (at pH = 12) B ⁺ = any cation, eg Na ⁺

Polyether chains are typical of non-ionic surfactants. Non-ionic surfactants do not form ions in an aqueous medium.

A. Anionic surfactants

As a rule, these are difficultly compatible with cationic surfactants, which makes their use according to the present invention difficult, although, e.g. in small quantities, is not excluded. Anionic surfactants to be used advantageously are acylamino acids (and their salts), such as

1. acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,

2. acyl peptides, for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,

3. Sarcosinates, for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,

4. taurates, for example sodium lauroyl taurate and sodium methyl cocoyl taurate,

5. Acyl lactylates, lauroyl lactylate, caproyl lactylate

6. Alaninate carboxylic acids and derivatives such as

1. carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecyienate,

2. ester carboxylic acids, for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,

3. ether carboxylic acids, for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,

Phosphoric acid esters and salts, such as, for example, DEA-oleth-10-phosphate and di-laureth-4 phosphate, Sulfonic acids and salts such as

1. acyl isethionates, e.g. Sodium / ammonium cocoyl isethionate,

2. alkylarylsulfonates,

3. alkyl sulfonates, for example sodium coconut monoglyceride sulfate, sodium Cι _2-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,

4. Sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate

as well as sulfuric acid esters, such as

1. alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium Cι _2-13 pareth sulfate,

2. Alkyl sulfates, for example sodium, ammonium and TEA lauryl sulfate.

B. Cationic surfactants

Cationic surfactants to be used advantageously

1. alkylamines,

2. alkylimidazoles,

3. Ethoxylated amines.

The large remaining group of quaternary nitrogen surfactants is represented by the group of active substances on which the invention is based.

C. Amphoteric surfactants

Amphoteric surfactants to be used advantageously

1. acyl- / dialkylethylenediamine, for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,

2. N-alkylamino acids, for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.

D. Non-ionic surfactants

Non-ionic surfactants to be used advantageously 1. alcohols,

2. alkanolamides, such as cocamides MEA / DEA / MIPA,

3. amine oxides, such as cocoamidopropylamine oxide,

4. esters which are formed by esterification of carboxylic acids with ethyl oxide, glycerol, sorbitol or other alcohols,

5. ethers, for example ethoxylated / propoxylated alcohols, ethoxyated / propoxylated esters, ethoxyated / propoxylated glycerol esters, ethoxyated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes and propoxylated POs Lauryl glucoside, decyl glycoside and cocoglycoside.

6. sucrose esters, ether

7 polyglycerol esters, diglycerol esters, monoglycerol esters 8. methyl glucose esters, esters of hydroxy acids

According to the invention, it is particularly advantageous to use a combination of quaternary nitrogen compounds with one or more amphoteric surfactants and / or with one or more nonionic surfactants.

Depending on the compatibility of the non-cationic surfactants with the quaternary nitrogen compound according to the invention, their concentration in preparations according to the invention can be up to 80% by weight, based on the total weight of the preparations.

In addition to the ingredients mentioned, the dermatological preparations according to the invention, the pH of which is preferably e.g. is adjusted to 4.0 to 7.5, in particular 5.0 to 6.5, by customary buffer mixtures, perfume, dyes, antioxidants, suspending agents, buffer mixtures or other customary cosmetic or dermatological base materials are added.

According to the invention, all the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.

It is also advantageous to add antioxidants to the preparations according to the invention. The antioxidants are advantageously selected from the group consisting of Amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine), carotenoids , Carotenes (e.g. α-carotene, ß-carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, liponic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, Cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, paimitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilaurylthiodi - propionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine doses) in very low dosages (e.g. pmol to μmol / kg), also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. cftronic acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (eg ascorbyl palmitate, Mg-ascorbyl phosphate, as - corby acetate), tocopherols and derivatives (eg vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, α-glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butyl hyroxroxy toluene , Butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO ₄ ) selenium and its derivatives (for example selenium methionine), stiibenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances which are suitable according to the invention.

The amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation .

If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation. If vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to have their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.

It is advantageous for the present invention that the pH of the dermatological preparations according to the invention is less than 8. pH values that are slightly higher than 7 but less than 7.5 can generally be tolerated. In any case, it is easy to determine for a given fatty acid mixture by simply trying it out, without inventive step, which exact upper pH limit is to be observed.

The pH of the formulations according to the invention is advantageously adjusted to less than 8 in the acidic to very weakly alkaline range, preferably from 4.0 to 7.5, particularly preferably from 5.0 to 6.5.

The amounts of auxiliary additives and carriers and possibly perfume to be used can easily be determined by a person skilled in the art by simply trying them out, depending on the type of product in question.

With the exception of special preparations, each of which is noted separately in the examples, the dermatological preparations according to the invention are prepared in a customary manner, usually simply by mixing with stirring, optionally with gentle heating. It has no difficulties. For emulsions fat phase and water phase e.g. prepared separately, optionally with heating and then emulsified.

Otherwise, the usual measures for compiling galenic formulations, which are familiar to the person skilled in the art, must be observed.

If the combinations according to the invention are to be incorporated into powder, the suspension bases for this can advantageously be selected from the group Silicic acid gels (eg those available under the trade name Aerosil®), kieselguhr, talc, modified starch, titanium dioxide, silk powder, nylon powder, polyethylene powder and related substances.

Advantageous exemplary embodiments of the present invention follow. The quantities always relate to% by weight, unless otherwise stated.

example 1

W / O cream

% By weight

Paraffin oil (DAB 9) 10.00

Petrolatum 4.00

Wool wax alcohol 1.00

PEG-7 hydrogenated castor oil 3.00

Aluminum stearate 0.40

Polyaminopropyl biguanide 0.20

Glycerin 2.00

Preservatives, dyes, perfume q.s.

Water ad 100.00

Example 2

W / O lotion

% By weight

Paraffin oil (DAB 9) 20.00

Petrolatum 4.00

Glucose sesquiisostearate 2.00

Aluminum stearate 0.40

Cetyltrimethylammonium chloride 0.10 α-tocopheryl acetate 1.00

Glycerin 5.00

Preservatives, dyes, perfume q.s.

Water ad 100.00 Example 3

O / W lotion

% By weight

Paraffin oil (DAB 9) 8.00

Isopropyl palmate 3.00

Petrolatum 4.00

Cetylstearyl alcohol 2.00

PEG-40 castor oil 0.50

Sodium cetyl stearyl sulfate 0.50

Sodium carbomer 0.40

Polyaminopropyl biguanide 0.20

Glycerin 3.00 α-tocopherol 0.20

Octyl methoxycinnamate 5.00

Butyl methoxydibenzoyl methane 1.00

Preservatives, dyes, perfume q.s.

Water ad 100.00

Example 4

O / W cream

% By weight

Paraffin oil (DAB 9) 7.00

Avocado oil 4.00

Glyceryl monostearate 2.00

Cetyltrimethylammonium chloride 0.10

Titanium dioxide 1.00

Sodium lactate 3.00

Glycerin 3.00

Preservatives, dyes, perfume q.s.

Water ad 100.00 Example 5

O / W cream

% By weight

Quartzrnium-5 3.50

Paraffin oil, subliquidum 10.00

Cetearyl alcohol 2.00

Hydrogenated coconut fatty acid glycerides 0.50

Dimethicone 0.75

Glycerin 20.00

Tocopherol acetate 0.50

Polyaminopropyl biguanide 0.20

Preservatives, dyes, perfume q.s. Water ad 100.00

Example 6

O / W cream

% By weight

Quarternium-5 3.50

Paraffin oil, subliquidum 10.00

Cetearyl alcohol 2.00

Hydrogenated coconut fatty acid glycerides 0.50

Dimethicone 0.75

Glycerin 20.00

Tocopherol acetate 0.50

Preservatives, dyes, perfume q.s.

Water ad 100.00 Example 7

Gel containing liposomes

% By weight

Lecithin 6.00

Ski butter 3.00

Cetyltrimethylammonium chloride 0.10 α-tocopherol 0.20

Biotin 0.08

Sodium citrate 0.50

Glycine 0.20

Urea 0.20

Sodium PCA 0.50

Hydrolyzed collagen 2.00

Xanthan gum 1.40

Sorbrtol 3.00

Preservatives, dyes, perfume q.s.

Water ad 100.00

Example 8

gel

% By weight

Carbopol 934 P 2.00

Triethanolamine 3.00

Polyaminopropyl biguanide 0.20 α-tocopheryl acetate 0.20

Polyoxyethylene sorbitan fatty acid ester (Tween 20) 0.50

Glycerin 2.00

Sodium PCA 0.50

Hydrolyzed collagen 2.00

Preservatives, dyes, perfume q.s.

Water ad 100.00

Claims

Claims:

1. Use of quaternary nitrogen compounds for the prophylaxis and treatment of superinfected atopic eczema.

2. Use according to claim 1, characterized in that the quaternary nitrogen compounds in concentrations of 0.01-99.00% by weight, preferably 0.05-50.00% by weight, particularly preferably 0.1-10, 00 wt .-%, based in each case on the total weight of the composition.